Lupin Limited (LUPIN)

Price1,097.45 -29.85 (-2.65%)52 Week High1,174.50
ISININE326A0103752 Week Low628.00
IndustryPharmaceuticals: OtherVolume1.3 M
SectorHealth TechnologyP/E Ratio TTM51.59
Market Cap513.9 B1 Year Beta0.46
Technical Rating of

Lupin Limited (LUPIN) logo

Lupin Limited (LUPIN) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. It was founded in 1968 by Mr. Desh Bandhu Gupta. LUPIN is one of the largest pharmaceutical companies in India, with a market capitalization of over $20 billion. The company manufactures a wide range of generic and branded pharmaceutical products, including anti-infectives, anti-diabetics, and cardiovascular drugs. LUPIN’s customers include a wide range of hospitals, clinics, and pharmacies in India and abroad.

LUPIN has been profitable for over 54 years and has a strong balance sheet. The company is well-positioned to grow in the coming years, due to the increasing demand for generic and branded pharmaceutical products in India and abroad. However, there are also some risks associated with investing in LUPIN, such as competition from other Indian and international pharmaceutical companies, regulation by the government of India and other countries, economic slowdown, and changing technologies.

Here are some of the key aspects of Lupin Limited (LUPIN):

  • Products and services: LUPIN manufactures a wide range of generic and branded pharmaceutical products, including anti-infectives, anti-diabetics, and cardiovascular drugs.
  • Customers: LUPIN’s customers include a wide range of hospitals, clinics, and pharmacies in India and abroad.
  • Financial performance: LUPIN has been profitable for over 54 years and has a strong balance sheet.
  • Market share: LUPIN is one of the largest pharmaceutical companies in India, with a market capitalization of over $20 billion.
  • Growth potential: LUPIN is well-positioned to grow in the coming years, due to the increasing demand for generic and branded pharmaceutical products in India and abroad.

Here are some additional details about LUPIN:

  • The company has a strong research and development (R&D) team that is constantly working to develop new products and technologies. This helps the company to stay ahead of the competition and meet the changing needs of its customers.
  • LUPIN has a strong brand name and reputation for quality. This helps the company to attract customers and command a premium price for its products.
  • LUPIN is committed to sustainability. The company has a number of initiatives in place to reduce its environmental impact, such as using water-saving technologies and renewable energy sources.

Overall, Lupin Limited (LUPIN) is a well-managed company with a strong track record of financial performance. The company is also one of the largest pharmaceutical companies in India with a bright future.

Here are some of the risks associated with investing in Lupin Limited (LUPIN):

  • Competition: LUPIN faces competition from other Indian and international pharmaceutical companies.
  • Regulation: The pharmaceutical industry is regulated by the government of India and other countries. This regulation could impact LUPIN’s business in the future.
  • Economic slowdown: If the Indian or global economy slows down, it could impact LUPIN’s business.
  • Changing technologies: The pharmaceutical industry is constantly evolving with new technologies. LUPIN needs to be able to adapt to these changes in order to remain competitive.

Ultimately, the decision of whether or not to invest in Lupin Limited (LUPIN) is a personal one. You should carefully consider your individual investment goals and risk tolerance before making a decision.

          

Lupin Limited (LUPIN) Chart

Technical Analysis of Lupin Limited (LUPIN)

Moving Averages

PeriodSimpleExponential
MA 51,132.911,125.31
MA 101,135.931,128.90
MA 201,121.351,118.03
MA 301,110.161,099.65
MA 501,059.041,057.39
MA 100939.16969.18
MA 200823.34878.67

Moving Average Rating

Technical Indicators

NameValueNameValue
Aroon Up (14)50.00Aroon Down (14)0.00
MACD Level (12, 26)20.31MACD Signal (12, 26)27.03
Relative Strength Index (7)32.13Relative Strength Index (14)47.46
Stochastic %D (14 3 3)56.16Stochastic %K (14 3 3)41.46
Stochastic RSI Fast (3, 3, 14, 14)14.64Stochastic RSI Slow (3, 3, 14, 14)27.08
Bollinger Upper Band (20)1,166.56Bollinger Lower Band (20)1,076.14
Keltner Channels Upper Band (20)1,169.34Keltner Channels Lower Band (20)1,066.71
Donchian Channels Upper Band (20)1,174.50Donchian Channels Lower Band (20)1,072.20
Ichimoku Conversion Line (9, 26, 52, 26)1,133.00Ichimoku Base Line (9, 26, 52, 26)1,119.30
Ichimoku Leading Span A (9, 26, 52, 26)1,053.51Ichimoku Leading Span B (9, 26, 52, 26)974.37
Positive Directional Indicator (14)24.02Negative Directional Indicator (14)20.87
Volume Weighted Average Price1,107.73Volume Weighted Moving Average 201,124.65

Oscillator Rating

Oscillators

Awesome Oscillator31.03
Ultimate Oscillator (7,14,28)38.88
Money Flow (14)66.20
Chaikin Money Flow (20)-0.14
Commodity Channel Index (20)-48.29
Bull Bear Power-28.22

High / Low

1 Month1,174.501,072.20
3 Month1,174.50852.35
6 Month1,174.50628.00
52 Week1,174.50628.00
All Time2,129.006.11

Volume

Volume1.3 M
Average 10 D1.1 M
Average 30 D1.1 M
Average 60 D1.2 M
Average 90 D1.2 M

Change/Volatility

Change-29.85 (-2.65%)
Change 1W-53.25 (-4.63%)
Change 1M-0.40 (-0.04%)
Volatility3.92
Volatility W2.58

Performance

Yesterday49.33
Weekly-5.58
Monthly0.50
3 Month28.89
6 Month68.58
Yearly67.35
5 Year22.48
All Time14,540.08

Misc.

Average Day Range (14)24.37
Average Directional Index (14)54.29
Average True Range (14)25.23
Williams Percent Range (14)-92.83
Rate Of Change (9)-2.76
Hull Moving Average (9)1,124.70
Momentum (10)-38.75
Parabolic SAR1,174.50

PIVOT POINTS of Lupin Limited (LUPIN)

NameS3S2S1Pivot PointsR1R2R3
Classic734.37903.321,000.581,072.271,169.531,241.221,410.17
Fibonacci903.32967.861,007.731,072.271,136.811,176.681,241.22
Camarilla1,051.391,066.881,082.361,072.271,113.341,128.821,144.31
Woodie's842.53908.761,011.481,077.711,180.431,246.661,349.38
DeMark's - - 1,036.431,090.191,205.38 - -

Financial Analysis of Lupin Limited (LUPIN)

Income Statement

Basic EPS (FY)9.46
Basic EPS (TTM)21.35
EBITDA (Annual YoY Growth)-20.51
EBITDA (Quarterly QoQ Growth)41.79
EBITDA (Quarterly YoY Growth)422.43
EBITDA (TTM)24.1 B
EBITDA (TTM YoY Growth)81.96
EPS Diluted (FY)9.41
EPS Diluted (MRQ)6.74
EPS Diluted (Quarterly QoQ Growth)91.86
EPS Diluted (TTM)21.27
EPS Forecast (MRQ)8.48
Free Cash Flow Margin (FY)1.23
Gross Profit (Annual YoY Growth)-1.15
Gross Profit (FY)72.2 B
Gross Profit (MRQ)20.9 B
Gross Profit (Quarterly QoQ Growth)27.46
Gross Profit (Quarterly YoY Growth)7.88
Gross Profit (TTM YoY Growth)-0.24
Last Year Revenue (FY)164.9 B
Revenue (Annual YoY Growth)1.05
Revenue per Employee (FY)8.8 M
Revenue (Quarterly QoQ Growth)8.67
Revenue (Quarterly YoY Growth)28.59
Revenue (TTM YoY Growth)11.54
Net Income (FY)4.3 B
Net Income (Quarterly QoQ Growth)91.67
Total Revenue (FY)164.9 B

Valuation

Enterprise Value/EBITDA (TTM)21.32
Number of Employees18,731.00
Number of Shareholders357 T
Shares Float241.8 M
Price to Book (FY)4.01
Price to Earnings Ratio (TTM)51.59
Price to Revenue Ratio (TTM)2.83
Price to Sales (FY)3.04
Total Shares Outstanding455.2 M
Research & development Ratio (FY)7.12
Research & development Ratio (TTM)6.74
Selling & Admin expenses Ratio (FY)30.54
Selling & Admin expenses Ratio (TTM)32.06

Balance Sheet

Total Assets (Annual YoY Growth)5.20
Total Debt (Annual YoY Growth)9.21
Total Liabilities (FY)104.1 B
Cash & Equivalents (FY)12.5 B
Cash and short term investments (FY)17.3 B

Operating Metrics

Dividends

Dividend Yield Forward0.35
Dividends Paid (FY)-1,825,000,000.00
Dividends per Share (FY)4.00

Margins

Net Margin (FY)2.61
Net Margin (TTM)5.48
Gross Margin (FY)43.81
Gross Margin (TTM)47.21
Operating Margin (FY)5.04
Operating Margin (TTM)8.40
Pretax Margin (TTM)7.19

Lupin Limited (LUPIN) FUTURES

ExpiryOpenHighLowCloseSettleContractsValueOIOI Change
28-Sep-231,124.851,134.001,093.751,100.401,100.404 T37.4 T5.3 M-413,950
26-Oct-231,133.001,140.701,101.251,107.751,107.751.5 T13.9 T821.1 T345.1 T
30-Nov-231,120.001,126.001,113.351,113.351,112.451817131.5 T3.4 T

Lupin Limited (LUPIN) OPTIONS

Related Companies (Peers) to Lupin Limited (LUPIN)

Price635.95 2.00 (0.32%)52 Week High775.45
ISININE098F0103152 Week Low554.05
IndustryPharmaceuticals: OtherVolume32,284
SectorHealth TechnologyP/E Ratio TTM43.12
Market Cap18.5 B1 Year Beta0.88
Technical Rating of
Amrutanjan Health Care Limited (AMRUTANJAN) is an Indian pharmaceutical company headquartered in Hyderabad, India. It was incorporated in 1965. The company’s initial focus was on the manufacturing of pain relief balms. Amrutanjan has since expanded its operations to include a wide range of over-the-counter (OTC) products, including cough syrups, cold remedies, and skin care products. more about Amrutanjan Health Care Limited (AMRUTANJAN)

Price866.40 -10.05 (-1.15%)52 Week High907.70
ISININE406A0103752 Week Low397.20
IndustryPharmaceuticals: OtherVolume1.4 M
SectorHealth TechnologyP/E Ratio TTM25.67
Market Cap513.3 B1 Year Beta0.66
Technical Rating of
Aurobindo Pharma Limited (AUROPHARMA) is an Indian multinational pharmaceutical company headquartered in Hyderabad, India. It was founded in 1986 by P. V. Ramana Rao. Aurobindo’s initial focus was on the manufacturing of generic pharmaceuticals. It has since expanded its operations to include a wide range of products, including APIs, finished dosages, and biosimilars. Aurobindo is more about Aurobindo Pharma Limited (AUROPHARMA)

Price1,185.90 -20.50 (-1.70%)52 Week High1,277.90
ISININE059A0102652 Week Low852.00
IndustryPharmaceuticals: OtherVolume2.8 M
SectorHealth TechnologyP/E Ratio TTM30.77
Market Cap974.5 B1 Year Beta0.06
Technical Rating of
Cipla Limited (CIPLA) is an Indian multinational pharmaceutical company headquartered in Mumbai, India. It was founded in 1935 by Khwaja Abdul Hamied. CIPLA is one of the largest pharmaceutical companies in India and has a global presence, with operations in over 150 countries. The company’s products include generic drugs, branded drugs, and over-the-counter (OTC) products. more about Cipla Limited (CIPLA)

Price336.80 13.60 (4.21%)52 Week High381.00
ISININE101D0102052 Week Low267.75
IndustryPharmaceuticals: OtherVolume3.8 M
SectorHealth TechnologyP/E Ratio TTM18.89
Market Cap78.2 B1 Year Beta0.79
Technical Rating of
Granules India Limited (GRANULES) is a well-established company with a strong track record in the Indian pharmaceutical industry. The company is a leading manufacturer of active pharmaceutical ingredients (APIs) and finished dosages in India. GRANULES has a strong customer base in the Indian and global pharmaceutical markets. GRANULES is well-positioned to capitalize on the growing more about Granules India Limited (GRANULES)

Price113.05 2.55 (2.31%)52 Week High155.90
ISININE933A0101452 Week Low88.50
IndustryPharmaceuticals: OtherVolume91,139
SectorHealth TechnologyP/E Ratio TTM
Market Cap3.7 B1 Year Beta0.96
Technical Rating of
Lyka Labs Limited (LYKALABS) is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. It was founded in 1990 by Mr. Rajesh Shah. LYKALABS is a leading manufacturer of generic APIs (active pharmaceutical ingredients) and finished dosage forms. The company’s products are used in a wide range of therapeutic areas, including anti-infectives, anti-diabetics, and cardiovascular drugs. more about Lyka Labs Limited (LYKALABS)

Lupin Limited (LUPIN) Related Indices

The Nifty 200 Index is designed to reflect the behaviour and performance of large and mid market capitalization companies . Nifty 200 includes all companies forming part of Nifty 100 and Nifty Full Midcap 100 index. The Nifty 200 Index represents about 86% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 77% of the traded value of all stocks on NSE. more about Nifty 200

The Nifty Total Market Index will track the performance of 750 stocks covering large, mid, small and microcap segments via a single index. All stocks that are part of Nifty 500 index and Nifty Microcap 250 index form part of the Nifty Total Market index. Stock’s weight is based on its free-float market capitalization. more about Nifty Total Market

The Nifty 500 represents the top 500 companies based on full market capitalisation and average daily turnover from the eligible universe. It represents about 94% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all Index constituents is approximately 87% of the traded value of all stocks on NSE. more about Nifty 500

The Nifty500 Multicap 50:25:25 index aims to measure the performance of portfolio of large, mid and small market capitalisation companies with target weights assigned to each size segment. The Nifty500 Multicap 50:25:25 index includes all companies that are part of Nifty 500 index. While in Nifty 500 index, the total weight of each size segment (Large, Mid and Small cap) is based on the total free float market capitalisation of all stocks falling within that size segment, in Nifty500 Multicap 50:25:25 index, the total weight of each of these three segments (Large, Mid and Small cap) is fixed at 50%, 25% and 25% respectively at every quarterly rebalance date. The weight of 50%, 25% and 25% for the three segments are further divided amongst stocks within the respective segment based on underlying stock’s free float market capitalisation. Weight of each size segment may be different from its respective capped level between two rebalance dates due to price drift of underlying stocks. more about Nifty500 Multicap 50:25:25

Nifty Midcap 150 represents 150 companies (companies ranked 101-250) based on full market capitalisation from Nifty 500. The Nifty Midcap 150 Index represents about 11.4% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 19% of the traded value of all stocks on NSE. more about Nifty Midcap150

Nifty Midcap 50 index represent top 50 companies based on full market capitalisation from Nifty Midcap 150 index and on which derivative contracts are available on National Stock Exchange (NSE). more about Nifty Midcap 50

The Nifty Midcap 100 Index captures the movement of the midcap segment of the market. The Nifty Midcap 100 Index comprises 100 tradable stocks listed on the National Stock Exchange (NSE). The Nifty Midcap 100 Index represents about 11% of the free float market capitalization of the stocks listed on NSE as on March 31, 2018. The total traded value for the last six months ending March 2018, of all index constituents is approximately 20% of the traded value of all stocks on NSE. more about Nifty Midcap 100

The Nifty LargeMidcap 250 reflects the performance of a portfolio of 100 large cap and 150 mid cap companies listed on NSE, represented through the Nifty 100 and the Nifty Midcap 150 index respectively. The aggregate weight of large cap stocks and mid cap stocks is 50% each and are reset on a quarterly basis. The index has a base date of April 01, 2005 and a base value of 1000. The Index is reconstituted on a semi-annual basis along with Nifty 100 and Nifty Midcap 150 index. more about Nifty LargeMidcap 250

The Nifty MidSmallcap 400 Index is designed to reflect the behaviour and performance of the mid and small market capitalisation companies. The Nifty MidSmallcap 400 Index represents about 17% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 28% of the traded value of all stocks on NSE. more about Nifty MidSmallcap 400

The Nifty Healthcare Index is designed to reflect the behaviour and performance of the Healthcare companies. The Nifty Healthcare Index comprises of maximum of 20 stocks that are listed on the National Stock Exchange. more about Nifty Healthcare

The Nifty Pharma Index is designed to reflect the behavior and performance of the pharmaceutical sector in India. more about Nifty Pharma

The Nifty India Manufacturing Index which aims to track the performance of the companies selected from the combined universe of Nifty 100, Nifty Midcap 150 and Nifty Smallcap 50 index based on 6 month average free-float market capitalisation within the eligible basic industries that broadly represent manufacturing sector. more about Nifty India Manufacturing

Nifty Low Volatility 50 Index tracks the performance of the least volatile securities listed on NSE In order to make the 50 stock index investible and replicable, criteria’s such as turnover and free float market capitalization are applied while selection of securities. Weights of securities in the index are assigned based on the volatility values. Least volatile security in the index gets the highest weight. more about Nifty Low Volatility 50

News Related to Lupin Limited (LUPIN)

  1. Sep 22, 2023, 8:19 pm

    Pharma Major Lupin Acquires 5 Legacy Brands from Menarini for Indian Market Pharma major Lupin Limited has acquired five legacy brands in strategic therapy areas from Menarini for the Indian market. The brands are Piclin, Menoctyl, Sucramal O, Pyridium, and Distaclor. This strategic acquisition is in line with Lupin's goal to broaden its presence in the Indian market and offer a comprehensive range of products. The five brands acquired by Lupin have a range of medicinal properties and are used to treat a variety of conditions, including constipation, irritable bowel syndrome, acidity, stomach ulcer, heartburn, pain, burning, increased urination, and increased urge to urinate.

  2. Sep 22, 2023, 4:46 pm

    Pharma Sector Sees Bearish Sentiment on September 22 The pharmaceutical sector is experiencing bearish sentiment on September 22, with profit-booking pressure and short positions in several individual stocks, including Glenmark, Cipla, Alkem, and Dr Reddy's. Analysts believe that the Nifty Pharma Index could see further weakness if it breaks below the 14700-14800 support zone. On the other hand, Aurobindo Pharma is seen as a moderately bullish stock, with strong resistance at the 900 strike price and strong support at the 850 and 860 strike prices. Traders should be cautious and monitor the market closely for any further developments.

  3. Sep 12, 2023, 10:59 am

    Lupin shares rise 1.3% after announcing business transfer agreement Lupin shares rose after the company announced plans to enter into a business transfer agreement with its subsidiary. The move is expected to generate revenue for Lupin and analysts have retained their "hold" rating on the stock.

  4. Sep 12, 2023, 8:56 am

    Top 14 Business Headlines for September 12, 2023 Laurus Labs to acquire Laurus Bio for INR 71.60 crore. L&T increases buyback price to INR 3,200 per share. KKR to invest INR 2,069.50 crore in Reliance Retail Ventures. SpiceJet to complete payment of INR 100 crore to Kalanithi Maran. Several companies announce investment plans and expansion projects. ICICI Bank's Sandeep Bakhshi re-appointed as MD & CEO. Gufic Biosciences gets approval for Parecoxib Sodium in Australia and Brazil. PowerGrid wins transmission project in Rajasthan.

  5. Aug 15, 2023, 4:17 pm

    Manufacturing: The Next Big Thing for Mutual Funds Mutual funds are increasingly looking to manufacturing stocks as a way to generate alpha. After years of being overlooked by fund managers, manufacturing stocks are now seen as a potential source of growth and diversification. The global manufacturing sector is expected to grow at a faster pace than the overall economy in the coming years, and manufacturing stocks are becoming more attractively valued. As a result, mutual funds are increasingly adding manufacturing stocks to their portfolios. Some of the top midcap manufacturing stocks that are being picked by mutual funds include Bharat Forge, JSW Steel, Arvind Limited, Lupin Limited, and Motherson Sumi Systems.

More News >>

Leave a Reply

Your email address will not be published. Required fields are marked *

Stock Sectors
Stock Industries